Development
GSK plc
GSK
$41.30
$0.441.08%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 37.74B | 36.40B | 35.31B | 35.03B | 36.24B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 37.74B | 36.40B | 35.31B | 35.03B | 36.24B |
| Cost of Revenue | 11.03B | 10.69B | 10.46B | 10.77B | 12.07B |
| Gross Profit | 26.71B | 25.71B | 24.85B | 24.25B | 24.17B |
| SG&A Expenses | 11.39B | 10.99B | 10.56B | 10.20B | 10.07B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -1.80B | -1.12B | -1.02B | -647.76M | -886.37M |
| Total Operating Expenses | 27.75B | 27.40B | 26.55B | 26.69B | 27.60B |
| Operating Income | 9.99B | 9.00B | 8.76B | 8.34B | 8.63B |
| Income Before Tax | 7.54B | 8.98B | 7.90B | 6.54B | 7.04B |
| Income Tax Expenses | 939.85M | 964.63M | 913.55M | 799.13M | 897.44M |
| Earnings from Continuing Operations | 6.60K | 8.02K | 6.99K | 5.74K | 6.14K |
| Earnings from Discontinued Operations | -- | -5.87M | 11.84B | 12.01B | 12.42B |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -470.92M | -558.11M | -493.03M | -391.84M | -589.67M |
| Net Income | 6.13B | 7.45B | 18.34B | 17.36B | 17.97B |
| EBIT | 9.99B | 9.00B | 8.76B | 8.34B | 8.63B |
| EBITDA | 12.84B | 11.71B | 11.86B | 12.03B | 12.10B |
| EPS Basic | 1.51 | 1.84 | 4.55 | 4.31 | 4.46 |
| Normalized Basic EPS | 1.29 | 1.11 | 1.09 | 1.05 | 1.04 |
| EPS Diluted | 1.50 | 1.82 | 4.49 | 4.25 | 4.40 |
| Normalized Diluted EPS | 1.28 | 1.10 | 1.08 | 1.04 | 1.03 |
| Average Basic Shares Outstanding | 16.21B | 16.19B | 16.16B | 16.13B | 16.11B |
| Average Diluted Shares Outstanding | 16.41B | 16.38B | 16.36B | 16.33B | 16.31B |
| Dividend Per Share | 0.72 | 0.68 | 0.67 | 0.70 | 0.76 |
| Payout Ratio | 45.59% | 38.34% | 16.19% | 21.46% | 24.09% |